About 20%‐30% of NSCLC patients in Caucasian population and 8% of NSCLC patients in Asian population were observed to harbor KRAS mutation.15, 16, 17 In our cohort, 7.46% of Chinese NSCLC patients harbor KRAS mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.